An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

Katherine Stemke-Hale,1,7 Ana Maria Gonzalez-Angulo,1,2,7 Ana Lluch,8 Richard M. Neve,9 Wen-Lin Kuo,1 Michael Davies,1,2,7 Mark Carey,1 Zhi Hu,1 Yinghui Guan,1 Aysegul Sahin,1 W. Fraser Symmans,4 Lajos Puusztai,1 Laura K. Nolden,1 Hugo Horlings,1,11 Katrien Berns,11 Mien-Chie Hung,1,12 Marc J. van de Vijver,10 Vicente Valero,2 Joe W. Gray,9 René Bernardi,11 Gordon B. Mills,1,7 and Bryan T. Hennessy1,6,7

Departments of1 Systems Biology,2 Breast Medical Oncology,3 Melanoma Medical Oncology,3 Pathology,4 Molecular and Cellular Oncology, and5 Gynecologic Medical Oncology and6 Kleberg Center for Molecular Markers, The University of Texas M. D. Anderson Cancer Center, Houston, Texas;7 Universidad de Valencia Clinic Hospital, Valencia, Spain;8 Lawrence Berkeley National Laboratory, Berkeley, California; and9 Division of Experimental Therapy and10 Division of Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, Amsterdam, the Netherlands

Abstract

Phosphatidylinositol 3-kinase (PI3K)/AKT pathway aberrations are common in cancer. By applying mass spectrometry-based sequencing and reverse-phase protein arrays to 547 human breast cancers and 41 cell lines, we determined the subtype specificity and signaling effects of PIK3CA, AKT, and PTEN mutations and the effects of PIK3CA mutations on responsiveness to PI3K inhibition in vitro and on outcome after adjuvant tamoxifen. PIK3CA mutations were more common in hormone receptor–positive (34.5%) and HER2-positive (22.7%) than in basal-like tumors (8.3%). AKT1 (1.4%) and PTEN (2.3%) mutations were restricted to hormone receptor–positive cancers. Unlike AKT1 mutations that were absent from cell lines, PIK3CA (39%) and PTEN (20%) mutations were more common in cell lines than tumors, suggesting a selection for these but not AKT1 mutations during adaptation to culture. PIK3CA mutations did not have a significant effect on outcome after adjuvant tamoxifen therapy in 157 hormone receptor–positive breast cancer patients. PIK3CA mutations, in comparison with PTEN loss and AKT1 mutations, were associated with significantly less and inconsistent activation of AKT and of downstream PI3K/AKT signaling in tumors and cell lines. PTEN loss and PIK3CA mutation were frequently concordant, suggesting different contributions to pathophysiology. PTEN loss rendered cells significantly more sensitive to growth inhibition by the PI3K inhibitor LY294002 than did PIK3CA mutations. Thus, PI3K pathway aberrations likely play a distinct role in the pathogenesis of different breast cancer subtypes. The specific aberration present may have implications for the selection of PI3K-targeted therapies in hormone receptor–positive breast cancer. [Cancer Res 2008;68(15):6084–91]

Introduction

The phosphatidylinositol 3-kinase (PI3K) pathway mediates key cellular functions, including growth, proliferation, survival, angiogenesis, and motility (1). PI3K phosphorylates membrane phosphatidylinositol, thereby recruiting AKT and phosphoinositide-dependent kinase (PDK) 1 to the cell membrane. PDK1 and PDK2, likely the TORC2 complex, phosphorylate AKT and initiate a downstream signaling cascade. The tumor suppressor PTEN reverses the effects of PI3K by dephosphorylating the same site on membrane phosphatidylinositol (2). The growth factor receptor signaling and energy sensing LKB1-AMPK pathways integrate at the tuberous sclerosis complex (TSC), resulting in information transfer to the TORC1 complex and protein synthesis. In normal cells, the PI3K pathway is under tight homeostatic control through feedback regulatory loops that maintain normal cellular function and regulate glucose homeostasis (2).

Activating mutations in PIK3CA, PIK3R1, and AKT1 and inactivating mutations in PTEN, LKB1, and TSC2 are present in a broad range of tumor types (1). Further, germ-line mutations in PTEN, LKB1, and TSC result in hamartomatous cancer predisposition syndromes (Cowden’s, Peutz-Jeghers, and tuberous sclerosis, respectively). Additional pathway components, including PIK3CA, PIK3CB, AKT1 and AKT2, PDK1, p70S6 kinase (p70S6K), and TSC2, are frequently amplified in tumors. Because genomic aberrations can predict responsiveness to targeted therapies, and because multiple PI3K pathway members are frequently aberrant in breast tumors, targeting this pathway may provide a highly effective therapeutic approach (1, 3).

PIK3CA mutations, primarily at hotspots in exons 9 and 20 that encode portions of the helical and kinase domains of PI3K, have been reported to occur in approximately one third of breast cancers (4). These mutations have been reported to activate AKT and downstream signaling in model systems but their effects in patient tumors are unknown (5). PTEN mutations are relatively uncommon in breast cancer (<5%); however, PTEN protein loss (e.g., promoter methylation, loss of heterozygosity, and regulation at the RNA or protein level) is more common (~30%; ref. 1). A recent report identified a somatic mutation in the PH domain of AKT1 (E17K) in 8% of breast cancers in a small sample set (6). This mutation activates AKT1 by recruiting it to the membrane through a PI3K-independent mechanism (6). However, two large-scale sequencing studies failed to detect mutations at this site in any AKT isoform across multiple tumor types, raising the possibility...
that the former study overestimated the frequency of AKT1 mutations in breast cancer (7, 8). Although the frequencies of these mutations have been explored in small breast cancer sets, there has been no comprehensive analysis of the mutational frequency of multiple PI3K pathway members in a large breast cancer series representing the three major subtypes of hormone receptor–positive, HER2-positive, and basal-like tumors. As the cell origin, treatment, and outcomes are markedly different in the three breast cancer subtypes, it is critical that the effects of PI3K pathway aberrations on pathophysiology and therapy responsiveness are analyzed independently in each subtype. Recent studies from us and others implicate PIK3CA mutations and PTEN loss in resistance of HER2-positive breast cancers to trastuzumab (9, 10). However, the role of PI3K pathway aberrations in the clinical behavior and therapy responsiveness of hormone receptor–positive tumors remains controversial, in part due to analysis of small and clinically heterogeneous sample sets.

We thus determined the frequency, breast cancer subtype specificity, and signaling effects of PIK3CA, AKT, and PTEN mutations in human breast tumors and breast cancer cell lines. Further, we examined the effects of PIK3CA mutations on hormone receptor–positive breast cancer patient outcomes after adjuvant tamoxifen treatment.

### Materials and Methods

**Human breast tumor samples.** Human breast tumors were obtained from Tumor Banks following pathologist review under the auspices of Institutional Review Board–approved protocols at Clinic Hospital (Valencia, Spain; 306 tumors), the Netherlands Cancer Institute (34 tumors), and the M. D. Anderson Cancer Center. Frozen tissue from 547 tumors was used for DNA extraction (Table 1); protein was extracted from 306 tumors. Tumors were collected and frozen in liquid nitrogen within 1 h of surgical excision after review of the tumor and a frozen section by a pathologist. Of the 547 cancers (Table 1), tumors were characterized for estrogen receptor–positive, HER2-negative, and basal-like tumors. As the cell origin, treatment, and outcomes are markedly different in the three major breast cancer subtypes, it is critical that the effects of PI3K pathway aberrations on pathophysiology and therapy responsiveness are analyzed independently in each subtype. Recent studies from us and others implicate PIK3CA mutations and PTEN loss in resistance of HER2-positive breast cancers to trastuzumab (9, 10). However, the role of PI3K pathway aberrations in the clinical behavior and therapy responsiveness of hormone receptor–positive tumors remains controversial, in part due to analysis of small and clinically heterogeneous sample sets.

### Table 1. Frequency of mutations in the PIK3CA, AKT1, and PTEN genes in 547 human breast cancers and 41 breast cancer cell lines

<table>
<thead>
<tr>
<th>Tumor subtype</th>
<th>PIK3CA catalytic domain</th>
<th>PIK3CA other</th>
<th>PIK3CA total</th>
<th>PTEN</th>
<th>AKT1 E17K</th>
</tr>
</thead>
<tbody>
<tr>
<td>All human breast tumors</td>
<td>73/547 (13.3%)</td>
<td>44/547 (8.0%)</td>
<td>117/547 (21.4%)</td>
<td>2/88 (2.3%)</td>
<td>6/418 (1.4%)</td>
</tr>
<tr>
<td>Human breast HR+</td>
<td>48/232 (20.7%)</td>
<td>32/232 (13.8%)</td>
<td>80/232 (34.5%)</td>
<td>2/58 (3.4%)</td>
<td>6/232 (2.6%)</td>
</tr>
<tr>
<td>ER+PR+</td>
<td>39/186 (21%)</td>
<td>22/186 (11.8%)</td>
<td>61/186 (32.8%)</td>
<td>1/48 (2.1%)</td>
<td>6/186 (3.2%)</td>
</tr>
<tr>
<td>ER+PR-</td>
<td>9/41 (22%)</td>
<td>10/41 (24.4%)</td>
<td>19/41 (46.3%)</td>
<td>1/8 (12.5%)</td>
<td>0/41 (0%)</td>
</tr>
<tr>
<td>ER-PR+</td>
<td>0/5 (0%)</td>
<td>0/5 (0%)</td>
<td>0/5 (0%)</td>
<td>0/2 (0%)</td>
<td>0/5 (0%)</td>
</tr>
<tr>
<td>Human breast HER2+</td>
<td>13/75 (17.3%)</td>
<td>4/75 (5.3%)</td>
<td>17/75 (22.7%)</td>
<td>0/10 (0%)</td>
<td>0/75 (0%)</td>
</tr>
<tr>
<td>Human breast TN</td>
<td>7/240 (5.0%)</td>
<td>8/240 (3.3%)</td>
<td>20/240 (8.3%)</td>
<td>0/20 (0%)</td>
<td>0/111 (0%)</td>
</tr>
<tr>
<td>All breast cancer cell lines</td>
<td>7/41 (17.1%)</td>
<td>9/41 (22%)</td>
<td>10/41 (24.4%)</td>
<td>3/19 (15.8%)</td>
<td>0/19 (0%)</td>
</tr>
<tr>
<td>Breast cancer cell lines HER2+</td>
<td>4/19 (21%)</td>
<td>2/19 (10.5%)</td>
<td>6/19 (31.6%)</td>
<td>3/19 (15.8%)</td>
<td>0/19 (0%)</td>
</tr>
</tbody>
</table>

Abbreviations: HR+, hormone receptor positive; TN, triple negative.

2. Other PIK3CA mutations include E545K, E542K, N345K, E418K, and P539R in order of frequency.
3. Resequencing courtesy of Len Pennacchio and Jan-Fang Cheng of Lawrence Berkeley National Laboratory in breast cancers and by literature/internet (e.g., http://www.sanger.ac.uk) search in cell lines.
4. Two distinct PIK3CA mutations were found together in four patients with hormone receptor–positive breast cancer (PIK3CA_H1047R with PIK3CA_E545K, PIK3CA_H1047Y with PIK3CA_E542K, PIK3CA_H1047R with PIK3CA_K111N, and PIK3CA_E418K with PIK3CA_E418K).
5. DNA extraction in these tumors courtesy of Mandy Madiredjo at The Netherlands Cancer Institute.
6. One triple-negative breast cancer cell line (BT20) had both a catalytic domain H1047R and a noncatalytic domain P539R mutation in PIK3CA.

Mass spectroscopy–based approach evaluating single nucleotide polymorphisms. A mass spectroscopy–based approach evaluating single nucleotide polymorphisms (SNP) was used to detect the AKT1_E17K mutation, mutations in the equivalent sites of AKT2 and AKT3, and 23 known mutations in PIK3CA (PIK3CA_A1046V, PIK3CA_C420R, PIK3CA_E110K, PIK3CA_E418K, PIK3CA_E543K, PIK3CA_E542K, PIK3CA_E453K, PIK3CA_F909L, PIK3CA_G1049R, PIK3CA_G451L/G456V, PIK3CA_H1047L, PIK3CA_H1047Y, PIK3CA_H701P, PIK3CA_K111N, PIK3CA_M1043V, PIK3CA_N345K, PIK3CA_P539R, PIK3CA_Q660K, PIK3CA_Q546E, PIK3CA_R0858Q, PIK3CA_S450F, and PIK3CA_T1025S; refs. 11, 12). PCR and extension primers for PCR and extension primers for other

Hybridization (FISH; Table 1) and FISH = 190. HER2 positivity was designated when 3+ membranous staining occurred in >10% of tumor cells or with ligand binding of >2.0, or with a log2 mean fluorescence in situ hybridization (FISH; n = 357) or by reverse-phase protein array (RPPA; n = 190). HER2 positivity was designated when 3+ membranous staining occurred in >10% of tumor cells and/or with a HER2 to CEPI ratio of >2.0, or with a log2 mean centered cutoff of +0.82 by RPPA (this cutoff predicts HER2 positivity by immunohistochemistry/FISH with a sensitivity of ~80% and a specificity of 96–100%).

Tumors were designated as basal-like (i.e., triple receptor negative) when they were negative for HER2, ER, and PR expression. DNA and protein from breast cancer cell lines (Supplementary Table S1) were obtained from Lawrence Berkeley National Laboratory at the University of California at San Francisco.

PIK3 Pathway Mutations in Breast Cancer

---


Downloaded from cancerres.aacrjournals.org on April 13, 2017. © 2008 American Association for Cancer Research.
Spectrochip matrix chips using a nanodispenser (Samsung). Chips were run in duplicate on a Sequenom MassArray MALDI-TOF MassArray system. Sequenom Typer Software and visual inspection were used to interpret mass spectra. Reactions where >15% of the resultant mass ran in the mutant site in both reactions were scored as positive. AKT1_E17K mutations were specifically confirmed with independent primers. All mutations were confirmed by Sanger sequencing in the M. D. Anderson Cancer Center Cancer Center Support Grant–supported sequencing core. Results were concordant in all cases.

**PTEN sequencing.** A high-throughput approach to the resequencing of PTEN and PIK3CA was performed on 88 breast cancers following whole-genome amplification (13). The resequencing protocol was as follows: oligonucleotide primers (sequences available on request) for amplifying the gene coding exons were designed to give a product size in the range of 200 to 700 bp with a minimum of 40 bp flanking the splice sites using the Exon Primer program, which is bundled with the University of California at Santa Cruz Genome Browser (build hg17). M13F and M13R tags were added to the forward and reverse primers, respectively. Five nanograms of genomic DNA from each breast tumor were amplified in an 8-L PCR using AmpliTaq Gold (Applied Biosystems) on PE 9700 machines and subsequently cleaned using a diluted version of the EXO-SAP–based PCR product presequencing kit (USB Corp.) dispensed by a nanoliter dispenser (Deerac Fluidics Equator, Inc.). All PCR set-up procedures were performed in a 384-well format using a Biomek FX workstation after optimization. Sequencing reactions were then performed using the M13 primers along with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and cleaned with BET before separation on an ABI 3730xl DNA Analyzer. Base calling, quality assessment, and assembly were carried out using the Phred, Phrap, Polymiph, Consed software suite. All sequence variants identified were verified by manual inspection of the chromatograms. Mutation frequencies determined using this approach should be considered lower estimates as all exon sequences were not covered in all subjects with perfect mutation capture. In contrast, the false-positive rate with this approach is low to nonexistent (13).

**Reverse-phase protein lysate microarray.** RPPA as performed in our laboratory has been described previously (14, 15) and was used to quantify PTEN expression and phosphorylation of AKT at Thr308 and Ser473, glycogen synthase kinase 3 (GSK3) at Ser21, mammalian target of rapamycin (mTOR) specific antibodies), Epitomics, Inc. (total p70S6K antibody), and Santa Cruz Biotechnology (total GSK3 antibody). Because of potential effects of differences in tissue handling on protein phosphorylation in particular, 306 tumors from a single-institution batch (Clinic Hospital) were used for this analysis.

**Cell lines.** Twelve hormone receptor–positive breast cancer cell lines were cultured in complete medium (RPMI 1640 supplemented with 5% fetal bovine serum) and treated with LY294002 to determine the concentration resulting in 50% growth inhibition (GI50) in each cell line.

**Statistical analysis.** Group characteristics were tabulated and compared between groups with the χ² test or Kruskal-Wallis test as appropriate. One hundred and fifty-seven hormone receptor–positive breast cancers from patients treated with adjuvant tamoxifen were used for the outcome analyses. Overall survival (OS) was measured from the date of diagnosis to the date of death from any cause. Recurrence-free survival (RFS) was measured from the date of diagnosis to the date of breast cancer recurrence. Patients who died before experiencing a disease recurrence were considered censored at their date of death. Survival outcomes were estimated with the Kaplan-Meier method and compared between groups with the log-rank statistic. Multivariable Cox proportional hazards models were fit to determine the association of PIK3CA mutations with survival outcomes after adjustment for other patient characteristics.

**Results**

**Frequency of PIK3CA, AKT, and PTEN mutations in different breast cancer subtypes.** A mass spectroscopy–based approach using methods designed to detect SNPs (11, 12) was used to detect the AKT1_E17K mutation, mutations in the equivalent sites of AKT2 and AKT3, and mutations in PIK3CA in 547 breast cancers, primarily from Caucasian and Hispanic patients, and 41 cell lines (Table 1). This approach is more sensitive than conventional Sanger sequencing, having the potential to detect mutations that are present in only a subset of tumor cells or in tumors with high levels of normal cell contamination, which is commonly the case in breast cancer (11, 12). The AKT1_E17K mutation (Fig. 1) was detected in only 6 of 418 breast cancers (1.4%). An additional two tumors returned equivocal results due to potential AKT1_E17K mutation peaks comprising <15% of the area of the wild-type peak that could represent possible mutations. Nevertheless, although this confirms the likely role of AKT1_E17K mutations in breast cancer.

![Figure 1](image_url). Detection of PIK3CA and AKT1 mutations. A mass spectrometry tracing of an AKT1 E17K-mutant SNP allele in a hormone receptor–positive breast cancer. wt, wild type.

**Conclusions**

AKT1 mutations associated with increased risk of breast cancer recurrence were identified using a whole-genome amplification approach. The AKT1_E17K mutation was detected with high specificity but low sensitivity in breast cancer. A high-throughput approach to the resequencing of PTEN and PIK3CA was performed on 88 breast cancers following whole-genome amplification. PTEN sequencing was performed on 88 breast cancers following whole-genome amplification (13). The resequencing protocol was as follows: oligonucleotide primers (sequences available on request) for amplifying the gene coding exons were designed to give a product size in the range of 200 to 700 bp with a minimum of 40 bp flanking the splice sites using the Exon Primer program, which is bundled with the University of California at Santa Cruz Genome Browser (build hg17). M13F and M13R tags were added to the forward and reverse primers, respectively. Five nanograms of genomic DNA from each breast tumor were amplified in an 8-L PCR using AmpliTaq Gold (Applied Biosystems) on PE 9700 machines and subsequently cleaned using a diluted version of the EXO-SAP–based PCR product presequencing kit (USB Corp.) dispensed by a nanoliter dispenser (Deerac Fluidics Equator, Inc.). All PCR set-up procedures were performed in a 384-well format using a Biomek FX workstation after optimization. Sequencing reactions were then performed using the M13 primers along with BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) and cleaned with BET before separation on an ABI 3730xl DNA Analyzer. Base calling, quality assessment, and assembly were carried out using the Phred, Phrap, Polymiph, Consed software suite. All sequence variants identified were verified by manual inspection of the chromatograms. Mutation frequencies determined using this approach should be considered lower estimates as all exon sequences were not covered in all subjects with perfect mutation capture. In contrast, the false-positive rate with this approach is low to nonexistent (13).
cancer pathophysiology, the frequency is significantly lower than the 8% previously reported in a set of 55 breast cancers (6). AKT1_E17K mutations were restricted to hormone receptor–positive breast cancers expressing both ER and PR (6 of 186, 3.2%). No AKT1_E17K mutations were detected in 75 HER2-positive or 111 hormone receptor–negative and HER2-negative (triple receptor negative or basal like) breast cancers. AKT2_E17K and AKT3_E17K mutations were not detected in any sample, suggesting that they do not contribute to breast cancer pathophysiology.

PIK3CA mutations were detected in 117 of 547 breast cancers (21.4%), significantly more frequently than AKT1_E17K mutations (P < 0.0001). Of the 23 sites in PIK3CA that were assessed, mutations were detected in exon 20 that encodes the catalytic domain of PI3K (6 PIK3CA_H1047R, 2 PIK3CA_H1047I, 2 PIK3CA_H1047Y, and 1 PIK3CA_G1049R), in exon 9 that encodes the PI3K helical domain (31 PIK3CA_E545K and 6 PIK3CA_E542K), and at other sites (4 PIK3CA_N345K, 2 PIK3CA_E418K, and 1 PIK3CA_K111N). Four hormone receptor–positive breast cancers possessed two distinct PIK3CA mutations (PIK3CA_H1047R with PIK3CA_E545K, PIK3CA_H1047Y with PIK3CA_E545K, PIK3CA_H1047R with PIK3CA_K111N, and PIK3CA_E545K with PIK3CA_E418K). One triple-negative breast cancer cell line (BT20) also had both a catalytic domain (H1047R) and a noncatalytic domain mutation (P539R) in PIK3CA. Although AKT1_E17K mutations were restricted to hormone receptor–positive breast cancers, PIK3CA mutations were present in all breast cancer subtypes. However, PIK3CA mutations were more frequent in hormone receptor–positive (34.5%; P < 0.0001) and HER2-positive tumors (22.7%; P = 0.001) than triple receptor-negative or basal-like breast cancers (8.3%). There was no difference in the frequency of PIK3CA mutations between ER-positive and ER-negative/HER2-positive tumors (10 of 37 versus 7 of 37; P = 0.58). PTEN mutations were assessed in a subset of 88 patients by Sanger sequencing with only

Figure 2. Effects of PTEN loss and PIK3CA mutation on AKT activation in human breast tumors. PTEN and the two AKT phosphorylation sites (AKT_p308 and AKT_p473) were quantified using reverse-phase protein lysate array. The quantification data were then log transformed (base 2), mean centered, ordered by increasing PTEN expression level from above down, and plotted in the heat map shown. In the mean centering schema used, red indicates a relatively high level of (phospho)protein expression and green indicates a relatively low level of (phospho)protein expression. The level of PTEN expression is shown in lane 1 and the levels of AKT phosphorylation at Thr308 and Ser473 are shown in lanes 2 and 3, respectively. AKT phosphorylation was expressed as a ratio to total AKT expression for presentation in this figure. Clearly, AKT phosphorylation is strongly inversely correlated with PTEN protein expression. However, there is no clear association between PIK3CA mutation and AKT phosphorylation at either amino acid site. Further, there was no significant difference (P = 0.41) in the frequency of tumors with PIK3CA mutations among those tumors with the highest and lowest quartiles of PTEN expression (17 of 77 [22.1%] and 12 of 77 [15.6%], respectively). Tumors from one institution batch (i.e., from Clinic Hospital) were used for this analysis.
Thr308 and Ser473 in AKT had low PTEN levels. In contrast, there were almost all tumors with high levels of phosphorylation of both Thr308 and Ser473 were both present at significantly higher levels in protein expression value. As expected, AKT phosphorylation at groups ("PTEN low" and "PTEN high") using the median PTEN in human breast tumors (Fig. 2). The tumors were split into two characterized. We thus applied RPPA to determine if PTEN loss and effects of PI3K pathway but the functional proteomic analysis was repeated with PTEN-high tumors. However, no mutations in human tumors are not well mutations on AKT activation/ were not detected in 41 breast cancer cell lines (Supplementary Table S1), PIK3CA (16 of 41, 39%) and PTEN mutations (8 of 41, 20%) were more common in cell lines than patient tumors (Table 1). AKT_E17K, PIK3CA, and PTEN (where assessed) mutations were mutually exclusive in all patient tumors and breast cancer cell lines assessed.

**Figure 2.** Effect of aberrations in the PI3K pathway on PI3K pathway activation in breast cancer. PTEN loss is well known to activate the core PI3K signaling pathway but the functional proteomic effects of PIK3CA mutations in human tumors are not well characterized. We thus applied RPPA to determine if PTEN loss and PIK3CA mutations have similar effects on PI3K pathway signaling in human breast tumors (Fig. 2). The tumors were split into two groups ("PTEN low" and "PTEN high") using the median PTEN protein expression value. As expected, AKT phosphorylation at Thr308 and Ser473 were both present at significantly higher levels in PTEN-low compared with PTEN-high breast cancers ($P = 1.7 \times 10^{-16}$ and $7.9 \times 10^{-15}$, respectively), as were phosphorylation of mTOR ($P = 0.0008$) and p70S6K ($P = 3.6 \times 10^{-15}$). As indicated in Fig. 2, almost all tumors with high levels of phosphorylation of both Thr308 and Ser473 in AKT had low PTEN levels. In contrast, there were no significant differences in PTEN levels or in phosphorylation of AKT, GSK3, mTOR, or p70S6K between PIK3CA-mutant tumors, whether analyzed together or separately as catalytic and helical domain mutants, and PIK3CA wild-type breast tumors. To exclude the possibility of PTEN loss obscuring the effects of PIK3CA mutation on AKT and PI3K pathway activation, 153 breast cancers with PTEN protein levels below the median were removed and the analysis was repeated with PTEN-high tumors. However, no significant association was shown between PIK3CA mutation or mutation subtype and phosphorylation of AKT, GSK3, mTOR, or p70S6K in the subsequent analysis (data not shown). In contrast, AKT phosphorylation was increased in the three AKT1-mutant tumors in this set (Fig. 2) despite two of these mutant tumors having high PTEN levels. Thus, despite the clear association between PTEN protein levels and PI3K pathway activation, no clear association was present between PIK3CA mutation (or mutation subtype) and PI3K pathway activation in either human tumors (Fig. 2) or breast cancer cell lines (Fig. 3). Therefore, PTEN protein loss and PIK3CA mutations have markedly different functional effects on the PI3K pathway in breast cancer.

**PTEN but not PIK3CA mutations render cells sensitive to growth inhibition by the PI3K inhibitor LY294002.** The distinct functional proteomic effects of PIK3CA mutations and PTEN loss in hormone receptor–positive breast cancer suggest that these events may be associated with differential sensitivity to PI3K pathway-targeted therapies. Indeed, a low level of PTEN protein represented a major determinant of the sensitivity of 12 hormone receptor–positive breast cancer cell lines to the small-molecule PI3K inhibitor LY294002 (Fig. 4). In comparison with PTEN loss, PIK3CA mutations were associated with decreased sensitivity to LY294002.

**Correlation of PIK3CA mutations with outcomes in tamoxifen-treated hormone receptor–positive breast cancer patients.** Both the breast cancer subtype and the method of patient treatment influence patient outcomes, rendering it important to determine the effects of aberrations in the PI3K pathway on patient outcomes in well-characterized tumor sets with consistent treatment approaches. It has previously been reported that PTEN loss is associated with adverse outcomes in two mutations being found, both in hormone receptor–positive tumors.

Unlike AKT_E17K mutations that were not detected in 41 breast cancer cell lines (Supplementary Table S1), PIK3CA (16 of 41, 39%) and PTEN mutations (8 of 41, 20%)12 were more common in cell lines than patient tumors (Table 1). AKT_E17K, PIK3CA, and PTEN (where assessed) mutations were mutually exclusive in all patient tumors and breast cancer cell lines assessed.

**Figure 3.** Effect of PTEN and PIK3CA mutations on AKT activation/phosphorylation at Ser473 in 40 breast cancer cell lines. AKT phosphorylation at Ser473 (AKTp473) was significantly higher in PTEN-mutant cell lines than in PIK3CA-mutant (P = 0.005) or PTEN/PIK3CA wild-type (P = 0.001) cell lines. In contrast, there was no significant difference (P = 0.64) in AKT phosphorylation at Ser473 between PIK3CA-mutant and PTEN/PIK3CA wild-type cell lines. AKTp473 was quantified using RPPA and expressed on the Y axis after logarithmic conversion and mean centering.

**Figure 4.** The relative sensitivity of 12 hormone receptor–positive breast cancer cell lines to the PI3K inhibitor LY294002. LY294002 was applied to the panel of hormone receptor–positive breast cancer cell lines and the concentration causing 50% growth inhibition (GI50) was determined and presented as relative sensitivity ($-\log$ GI50). The cell lines are presented in order of increasing PTEN protein expression (lane A) as determined using RPPA: PTEN-low (P = 0.0007) and PTEN-mutant (P = 0.02) cell lines are significantly more sensitive to growth inhibition by LY294002 than PIK3CA-mutant cell lines. Lane B, AKT phosphorylation at Ser473 determined using RPPA [color coded as in lane A (i.e., green, low; black, mean; and red, high AKT phosphorylation)]. Lane C, cell line mutation status.

---

12 http://www.sanger.ac.uk
breast cancer (9, 10, 16). A recent study by us showed that PIK3CA mutations predict adverse outcomes after treatment with trastuzumab for HER2-positive breast cancer (10). There are currently insufficient PIK3CA mutations in basal tumors to perform a comprehensive analysis (Table 1). We were able to identify a sample set of 157 early-stage hormone receptor–positive tumors from patients treated with adjuvant tamoxifen. AKT and PTEN mutation status were not included in the outcome analyses due to the low frequency of these aberrations.

PIK3CA mutation status was not significantly associated with any measured clinical variable apart from nodal status (Supplementary Table S2) nor was it significantly associated with differential OS or RFS times in the 157 patients with early-stage tamoxifen-treated hormone receptor–positive breast cancer (Fig. 5; Supplementary Table S3). The specific PIK3CA mutation type [kinase domain versus all other (largely helical domain)] was also not significantly associated with differential patient outcomes (Fig. 5; Supplementary Table S3). In multivariable models in the 157 tumors including PIK3CA mutation status, age and stage at diagnosis, age at diagnosis (as a continuous variable), and stage (II/III versus I) were found to be significant predictors of OS, and only stage at diagnosis was found to be a significant predictor of RFS. Tumor grade was not included in the multivariable models due to missing data (see Supplementary Table S2).

**Discussion**

We have shown that PIK3CA pathway aberrations are common in breast cancer, pointing to a critical role for this signaling pathway in breast carcinogenesis. PIK3CA oncogene mutations are particularly common, whereas AKT and PTEN mutations occur less frequently (Table 1). The AKT1_E17K mutation was detected in only 6 of 418 breast cancers (1.4%), confirming a role in breast cancer pathophysiology albeit in a limited number of breast cancers. Amplification of PDK1, PIK3CA, PIK3CB, AKT1, AKT2, and p70S6K is also among the extensive list of known aberrations that can activate PI3K pathway signaling in cancer (1). The frequency of PI3K pathway mutational aberrations was markedly different among the different breast cancer subtypes, being most common in hormone receptor–positive tumors and least common in basal-like cancers. This breast cancer subtype specificity suggests that PIK3CA mutations and other PI3K pathway aberrations may play a distinct role in the pathogenesis of these different diseases. Further, because genomic aberrations can predict responsiveness to targeted therapies, and because multiple PI3K pathway members are frequently aberrant in human breast tumors through mutation and other anomalies, this creates an expectation that targeting this pathway will provide an effective therapeutic approach in breast cancer (1, 3). Genomic aberrations such as those studied herein may facilitate identification of patients who will benefit from PI3K pathway-targeted therapies.

PIK3CA and PTEN mutations have been reported to be mutually exclusive in many cancers with a notable exception being endometrial tumors (17, 18). In the breast cancer cell lines and tumors analyzed herein, AKT1_E17K, PIK3CA, and PTEN mutations were also mutually exclusive. PTEN loss and PIK3CA mutation have not been studied extensively but where they have, they have not been reported to be mutually exclusive, an observation confirmed herein (19).

PI3K pathway activation has been reported to be associated with poor outcomes in certain cancers (9). We have shown that an
integrated signature of PTEN protein loss and PIK3CA mutation in HER2-positive breast cancer is an even stronger predictor of trastuzumab resistance than either PIK3CA mutation or PTEN loss alone (9, 10). Herein, PIK3CA mutations were not associated with a significant effect on hormone receptor–positive breast cancer patient outcome after adjuvant tamoxifen therapy, compatible with the results of a previous study (19). Another recent study found that, although PIK3CA mutation status overall was not prognostic, the presence of helical domain mutations predicted a poor outcome whereas the presence of kinase domain mutations predicted an improved outcome (20). However, unlike our study, this study was not confined to a homogeneous group of breast cancer patients as described herein. Our study is the largest study to date of the outcome implications of PIK3CA pathway deregulation in a homogeneous group of patients with early-stage hormone receptor–positive breast cancer who received adjuvant tamoxifen. In contrast, it has previously been reported that PTEN loss is associated with adverse outcomes in breast cancer (9, 10, 16). Notwithstanding the lack of an outcome association with PIK3CA mutation status, there remains a high probability that appropriate PI3K pathway manipulation could alter outcomes for hormone receptor–positive breast cancer patients in response to hormonal manipulation or chemotherapy. However, a phase 3 trial of a mTOR inhibitor in combination with an aromatase inhibitor failed to show significant activity in an unselected hormone receptor–positive breast cancer patient population (21). Whether mTOR represents a suboptimal target for therapy in breast cancer, whether other combinations of therapies with mTOR inhibition will be effective, or whether feedback loops bypass the activity of mTOR inhibitors requires additional analysis (22). Novel PI3K- and AKT-targeted therapies are being introduced into trials [e.g., perifosine (Keryx), SF1126 (Semafore), BEZ2356 (Novartis), and EX147 (Exelixis)] with the expectation that these compounds may bypass feedback loops and have more efficacy than mTOR inhibitors. It is clear that a systems biology approach to kinase signaling interconnections will facilitate the rational implementation of drugs and particularly drug combinations targeting the PI3K pathway in breast cancers with different genomic aberrations targeting this pathway.

Unlike AKT1_E17K mutations that were not detected in 41 cell lines, PIK3CA and PTEN mutations were more common in cell lines than patient tumors (Table 1). A higher frequency of PIK3CA and PTEN mutations and PTEN mutations could be due to a failure to detect mutations in tumors as a result of technical factors. However, this alone is unlikely to account for these differences because AKT1 mutations should then be more readily identified in cell lines. Thus, there is likely to be a selection pressure for PIK3CA and PTEN but not AKT1_E17K mutations during adaptation to culture. Due to the low frequency of aberrations and the generally good outcome associated with hormone receptor–positive cancers, determining whether AKT1_E17K mutations contribute to patient outcomes and therapy responsiveness requires analysis of a large number of tumors. In our study, the breast tumors with AKT mutations had high AKT phosphorylation levels, although the low number precluded this from reaching statistical significance. However, none of the six patients with AKT1_E17K-mutant hormone receptor–positive tumors in this study has recurred, suggesting that AKT1 mutations may be associated with a good outcome. If confirmed in a larger series, this may indicate that AKT activation confers a selective advantage during early hormone receptor–positive tumorigenesis but inhibits tumor dissemination during progression. Consistent with this, although AKT1 is necessary for optimal initiation of tumorigenesis, it inhibits invasion and metastasis (23–25). AKT may thus be an initiating oncogene for hormone receptor–positive breast cancers but its anti-invasive properties may prevent disease progression contributing to a good prognosis.

As shown herein, PTEN protein loss and PIK3CA mutations have markedly different functional effects on activation of signaling through the PI3K pathway in human breast cancers and in breast cancer cell lines, likely leading to differential sensitivity to the pathway inhibitor LY294002. Thus, PI3K pathway activation by PTEN loss versus PIK3CA mutation could lead to different outcomes and is likely to have important implications for the use of pathway-targeted therapies in human tumors.

In summary, PI3K pathway aberrations are common in breast cancer, pointing to an important role for this signaling pathway in breast carcinogenesis and as a potential target for therapy. The clear breast cancer subtype specificity of these aberrations suggests that they may play a distinct role in the pathogenesis of different breast cancer subtypes. PI3K pathway aberrations are particularly common in hormone receptor–positive breast cancer. Despite the lack of an outcome association with common PIK3CA mutations, these mutations may have important implications for the clinical selection of targeted therapies in patients with hormone receptor–positive tumors that possess these aberrations.

**Disclosure of Potential Conflicts of Interest**

J.W. Gray: commercial research grants, GlaxoSmithKline, Cellgate, Affymetrix, and Cell Biosciences; consultant, Agenda, Cepheid, and Bristol-Myers Squibb. G.B. Mills: scientific/advisory committee member, Abbott Laboratories, Ambit Biosciences Corp., Lpath Therapeutics Inc., and Texas Institute for Genomic Medicine; consultant, GlaxoSmithKline, Semafore Pharmaceuticals Inc., and TAU Therapeutics; stock options, GLT, Inc.; royalty income, Upstate Biotechnology. The other authors disclosed no potential conflicts of interest.

**Acknowledgments**

Received 12/27/2007; revised 4/21/2008; accepted 5/30/2008.

**Grant support:** Kleberg Center for Molecular Markers at M. D. Anderson Cancer Center, American Society of Clinical Oncology Career Development Award, and National Cancer Institute grants 1R21CA121094-01 and 1R21CA120248-01 (A.M. Gonzalez-Angulo); The Susan G. Komen Foundation grant FAS0703849 (B.T. Hennessy, A.M. Gonzalez-Angulo, and G.B. Mills); National Cancer Institute grants P01CA16672, P50CA08369, and PO1CA99901 (G.B. Mills) and U.S. Department of Energy, Office of Science, Office of Biological and Environmental Research (contract DE-AC03-76SF00098) and NIH, National Cancer Institute grants P50 CA 58207 and U54 CA 112970 (J.W. Gray).

The costs of publication of this article were deferred in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**References**

6. Carpten JD, Faber AL, Horn C, et al. A transforming...
An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

Katherine Stemke-Hale, Ana Maria Gonzalez-Angulo, Ana Lluch, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/15/6084

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/07/28/68.15.6084.DC1

Cited articles
This article cites 24 articles, 13 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/15/6084.full.html#ref-list-1

Citing articles
This article has been cited by 100 HighWire-hosted articles. Access the articles at:
/content/68/15/6084.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.